SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 3.24 |
| Enterprise Value ($M) | -3.30 |
| Book Value ($M) | 2.67 |
| Book Value / Share | 0.62 |
| Price / Book | 1.21 |
| NCAV ($M) | 2.59 |
| NCAV / Share | 0.60 |
| Price / NCAV | 1.25 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -5.80 |
| Return on Assets (ROA) | -1.09 |
| Return on Equity (ROE) | -1.76 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.64 |
| Current Ratio | 1.64 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 6.66 |
| Assets | 6.74 |
| Liabilities | 4.07 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lind Global Fund II LP | 2.90 | 0.00 | |
| 13G | Sabby Management, Llc | 6.40 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 8,852 | 28,324 | 31.25 | |
| 65,459 | 130,005 | 50.35 | |
| 25,505 | 56,735 | 44.95 | |
| 34,369 | 172,964 | 19.87 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PULM – Pulmatrix, Inc. | QLGN – Qualigen Therapeutics, Inc. |
| RENB – Renovaro Inc. | RGC – Regencell Bioscience Holdings Limited |
| RGLS – Regulus Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io